Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MASCT-I and PD-1 Antibody in Advanced Gastric Cancer
NCT03393416Phase 1Unknown
- Sponsor
- HRYZ Biotech
- Start
- Apr 2018
- Primary completion
- Jul 2020
- Modality
- Whole Cell Cancer Vaccines, Allogeneic CAR-T, TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MASCT-I in gastric cancer (GC), sponsored by HRYZ Biotech. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 7 weeks. Status: unknown.
02
Drugs
MASCT-I
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT03393416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03393416.